Overview

Pharmacokinetic Study of VHX-896 and Iloperidone Tablets Under Steady-State Conditions

Status:
COMPLETED
Trial end date:
2024-10-24
Target enrollment:
Participant gender:
Summary
Study to compare the pharmacokinetics and pharmacodynamics of VHX-896 and iloperidone and evaluate the safety and tolerability of VHX-896 and iloperidone in patients with schizophrenia or bipolar I disorder under steady state conditions.
Phase:
PHASE1
Details
Lead Sponsor:
Vanda Pharmaceuticals
Treatments:
iloperidone